RECRUITINGPhase 4INTERVENTIONAL

Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.

The Effectiveness and Efficacy of the Combination of Pharmacotherapy With the Two New Recovery-oriented Programs, RECOVERYTRSGR (Treatment Resistant Schizophrenia) and RECOVERYTRSBDGR (Treatment Resistant Bipolar Disorder)

About This Trial

The effectiveness and efficacy of the combination of pharmacotherapy with the two new recovery-oriented programs, RECOVERYTRSGR for patients with treatment- resistant schizophrenia and RECOVERYTRSBDGR for patients with treatment- resistant bipolar disorder.

Who May Be Eligible (Plain English)

Who May Qualify: For patients with treatment resistant schizophrenia: - age 18-65 - IQ ≥ 80 - Diagnosis TRS. Inclusion criteria for patients with treatment resistant bipolar disorder: - age 18-65 - IQ ≥ 80 - Diagnosis TRSBD. Who Should NOT Join This Trial: For patients with treatment resistant schizophrenia: - Substance abuse and head injury. If substance abuse is successfully treated, the participant will be accepted into our program. - Relapse and hospitalization. Exclusion criteria for patients with treatment resistant bipolar diosrder: - Substance abuse and head injuries. If substance abuse is successfully treated, the participant will be acknowledged into our program. - Relapse and hospitalization. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: For patients with treatment resistant schizophrenia: * age 18-65 * IQ ≥ 80 * Diagnosis TRS. Inclusion criteria for patients with treatment resistant bipolar disorder: * age 18-65 * IQ ≥ 80 * Diagnosis TRSBD. Exclusion Criteria: For patients with treatment resistant schizophrenia: * Substance abuse and head injury. If substance abuse is successfully treated, the participant will be accepted into our program. * Relapse and hospitalization. Exclusion criteria for patients with treatment resistant bipolar diosrder: * Substance abuse and head injuries. If substance abuse is successfully treated, the participant will be acknowledged into our program. * Relapse and hospitalization.

Treatments Being Tested

COMBINATION_PRODUCT

Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),

A combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants) with RECOVERYTRSGR (psychotherapy) for patients with treatment-resistant schizophrenia. 190 sessions. 22 patients

COMBINATION_PRODUCT

Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,

The combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants) and TAU (psychotherapy) for patients with treatment-resistant schizophrenia. 190 sessions. The control group of Group A 20 patients

COMBINATION_PRODUCT

Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine

A combination of pharmacotherapy with RECOVERYTRSBDGR (antipsychotics, anxiolytics, antidepressants, mood stabilizers) for patients with treatment-resistant bipolar disorder. 140 sessions, 22 people

COMBINATION_PRODUCT

Group D (Pharmacotherapy and TAU)Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, seropram, lithium, depakine)

A combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants, mood stabilizers) and TAU (psychotherapy). A control group to RECOVERYTRSBDGR. 140 sessions. 20 people

Locations (1)

Private practice of Dr. S. Rakitzi and Dr. P. Georgila ILISION 34 15771 ATHENS GREECE

Athens, Greece